首页|氯吡格雷联合依折麦布治疗冠心病心绞痛的效果及安全性分析

氯吡格雷联合依折麦布治疗冠心病心绞痛的效果及安全性分析

扫码查看
目的 分析冠心病心绞痛临床治疗中应用依折麦布、氯吡格雷的效果及安全性.方法 选取 80 例冠心病心绞痛患者,随机分为研究组(40 例)、对照组(40 例).对照组单独使用依折麦布治疗,研究组使用依折麦布联合氯吡格雷治疗.比较两组临床指标、总胆固醇(TC)、甘油三酯(TG)、内皮素-1(ET-1)、一氧化氮(NO)以及用药安全性.结果 治疗后,研究组患者心绞痛持续时间(8.89±0.71)min/次短于对照组的(9.32±0.86)min/次,心绞痛发作频率(2.03±0.15)次/周低于对照组的(4.59±0.29)次/周,差异具统计学意义(P<0.05).治疗后,研究组患者TG、TC分别为(1.18±0.16)、(3.16±0.82)mmol/L,比对照组的(1.59±0.23)、(4.72±1.01)mmol/L低,差异具统计学意义(P<0.05).治疗后,研究组患者ET-1(67.45±5.23)ng/L低于对照组的(74.16±4.12)ng/L,而NO(82.57±5.18)μmol/L高于对照组的(71.73±4.15)μmol/L,差异具统计学意义(P<0.05).治疗后,研究组患者不良反应发生率7.50%与对照组的 10.00%比较,差异无统计学意义(P>0.05).结论 临床治疗冠心病心绞痛的过程中应用依折麦布、氯吡格雷联合治疗具有更加明显的疗效,能够改善患者的血脂水平,使其ET-1、NO指标得到改善,且患者联合用药后并不会有严重的不良反应,具有较高的安全性.
Effect and safety analysis of clopidogrel combined with ezetimibe in the treatment of angina pectoris of coronary heart disease
Objective To analyze the effect and safety of clopidogrel combined with ezetimibe in the treatment of angina pectoris of coronary heart disease.Methods A total of 80 patients with angina pectoris of coronary heart disease were randomly divided into a study group(40 cases)and a control group(40 cases).The control group was treated with ezetimibe alone,and the study group was treated with ezetimibe combined with clopidogrel.The clinical indicators,total cholesterol(TC),triglyceride(TG),endothelin-1(ET-1),nitric oxide(NO),and drug safety of the two groups were compared.Results After treatment,the duration of angina pectoris of(8.89±0.71)min/time in the study group was shorter than(9.32±0.86)min/time in the control group,and the frequency of angina pectoris of(2.03±0.15)times/week was lower than(4.59±0.29)times/week in the control group.The difference was statistically significant(P<0.05).After treatment,TG and TC in the study group were(1.18±0.16)and(3.16±0.82)mmol/L,which were lower than(1.59±0.23)and(4.72±1.01)mmol/L in the control group,and the difference was statistically significant(P<0.05).After treatment,ET-1 of(67.45±5.23)ng/L in the study group was lower than(74.16±4.12)ng/L in the control group,and NO of(82.57±5.18)μmol/L was higher than(71.73±4.15)μmol/L in the control group.The difference was statistically significant(P<0.05).After treatment,there was no significant difference in the incidence of adverse reactions between the study group(7.50% )and the control group(10.00% )(P>0.05).Conclusion In the clinical treatment of angina pectoris of coronary heart disease,the combined application of ezetimibe and clopidogrel has a more obvious effect,which can improve the blood lipid level and indicators of ET-1 and NO.Moreover,the combination of drugs in patients does not cause serious adverse reactions,which has a high safety.

ClopidogrelEzetimibeAngina pectoris of coronary heart diseaseClinical efficacySafety

李强、陈庆珍、王文韬、安兴、赵俊翔

展开 >

273200 泗水县中医医院心内科

氯吡格雷 依折麦布 冠心病心绞痛 临床疗效 安全性

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(18)